Paris, France-based Nanobiotix reported the results of its phase I/II clinical trial for NBTXR3, its liver cancer drug.
Here's what you need to know.
1. NBTXR3 is for patients with primary and metastatic tumors who can't undergo surgery and have few therapeutic options available.
Radiation has improved outcomes for these patients. NBTXR3 aims to amplify the energy dose within the tumor "to offer better clinical results and more therapeutic options to improve the poor prognosis of these populations."
2. In the trial, researchers treated two groups of patients with a 10 percent dose of NBTXR3 using either a 24 Gy or 45 Gy total radiation dose.
Nanobiotix didn't explore an intra-arterial injection because of the effectiveness of the Intra Tumoral injection.
3. The trial demonstrated both the feasibility of the treatment and the appropriate distribution of the injection. The product stays in the tumor with no leakage in surrounding tissue.
4. The 10 percent volume level has been successfully evaluated. Nanobiotix is recruiting new patients for an advanced clinical trial.
More articles on gastroenterology/endoscopy:
Exact Sciences' Cologuard available to Humana members & more — 4 GI company key notes
GI leader to know: Dr. Alan Ganderson of Gastroenterology of Virginia Beach
DoD honors Dr. Brent Lacey, Pensacola Naval Hospital for hepatitis C screening program: 5 key notes